Novelix Pharmaceuticals Share Price
78.30-1.20 (-1.51%)
+94.53% past 1 Year
Trimurthi Limited is a Public Limited Company having Registered Office situated at Hyderabad, Telangana. The company is into the business of Trading of Pharmaceuticals and related products and is into
Corporate filings & documents
Announcements
Submission of Intimation of AGM Date.
4 days agoSubmission of Intimation of AGM Date.
4 days agoSubmission of intimation of change in Designation of Director.
4 days agoSubmission of intimation of change in Designation of Director.
4 days agoSubmission of outcome of the board meeting.
5 days agoSubmission of outcome of the board meeting.
5 days agoNovelix Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/08/2026 inter alia to consider and approve Submission of Prior intimation of Board Meeting.
1 week agoNovelix Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/08/2026 inter alia to consider and approve Submission of Prior intimation of Board Meeting.
1 week agoSubmission of Intimation of Land Lease Deed.
2 weeks agoSubmission of Intimation of Land Lease Deed.
2 weeks agoSubmission of Newspaper Publication of the financial results for the quarter ended 30th June 2026.
2 weeks agoSubmission of Newspaper Publication of the financial results for the quarter ended 30th June 2026.
2 weeks agoSubmission of Statement of Deviation & Variation
3 weeks agoSubmission of Statement of Deviation & Variation
3 weeks agoSubmission of financial Results for the quarter ended 30th June 2026.
3 weeks agoSubmission of financial Results for the quarter ended 30th June 2026.
3 weeks agoSubmission of outcome of the Board meeting.
3 weeks agoSubmission of outcome of the Board meeting.
3 weeks agoNovelix Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 inter alia to consider and approve Submission of prior Intimation of Board meeting.
3 weeks agoNovelix Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 inter alia to consider and approve Submission of prior Intimation of Board meeting.
3 weeks agoSubmission of Certificate under Reg. 74(5) of SEBI (DP) Regulations 2018
1 month agoSubmission of Certificate under Reg. 74(5) of SEBI (DP) Regulations 2018
1 month agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Vupparapalli Chandrasekhar Reddy & Others
1 month agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Vupparapalli Chandrasekhar Reddy & Others
1 month agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Srinidhi Fine - Chemicals LLP & Others
1 month agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Srinidhi Fine - Chemicals LLP & Others
1 month agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Gattu Gnana Prakash & Others
1 month agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Gattu Gnana Prakash & Others
1 month agoSubmission of Intimation under regulation 7(2) of SEBI (PIT) Regulations 2015.
1 month agoSubmission of Intimation under regulation 7(2) of SEBI (PIT) Regulations 2015.
1 month agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Gattu Gnana Prakash & Others
1 month agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Gattu Gnana Prakash & Others
1 month agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Srinidhi Fine-Chemicals LLP & Narahari Belide
1 month agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Srinidhi Fine-Chemicals LLP & Narahari Belide
1 month agoSubmission of intimation of allotment of equity shares.
1 month agoSubmission of intimation of allotment of equity shares.
1 month agoSubmission of outcome of Board Meeting.
1 month agoSubmission of outcome of Board Meeting.
1 month agoSubmission of Voting results.
2 months agoSubmission of Voting results.
2 months agoSubmission of Voting Results along with Scrutinizers report.
2 months agoSubmission of Voting Results along with Scrutinizers report.
2 months agoSubmission of outcome of Extra Ordinary General Meeting.
2 months agoSubmission of outcome of Extra Ordinary General Meeting.
2 months agoSubmission of trading window closure intimation.
2 months agoSubmission of trading window closure intimation.
2 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Novelix Pharmaceuticals Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L67120TG1994PLC018956</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Nishita Kalantri <br/> Designation: Company Secretary and Compliance officer <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Bhoomika Choudhary <br/> Designation: Chief Financial Officer <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 22/06/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
2 months ago<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Novelix Pharmaceuticals Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L67120TG1994PLC018956</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Nishita Kalantri <br/> Designation: Company Secretary and Compliance officer <br/> EmailId: [email protected]</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Bhoomika Choudhary <br/> Designation: Chief Financial Officer <br/> EmailId: [email protected]</div> </div> <div> <br/> Date: 22/06/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
2 months agoSubmission of newspaper publication of corrigendum to the EGM Notice.
2 months agoSubmission of newspaper publication of corrigendum to the EGM Notice.
2 months agoAnnual reports
Concalls & investor presentations
No presentations found
Corporate Actions
Date
Type
Details
No data available.
Company details
Registered office
Amrutha Estates, 6th Floor H. No. 3-6-237/610, Lingapur La Builders Himayath Nagar Hyderabad Telangana PIN: 500029 Tel No: 8977631044 Fax No: 040-24757370 Email: [email protected] Internet: https://novelixpharma.com
Registrars
Aurum, Door No 4-50/P-II/57/4F&5F Plot No 57, 4th & 5th Floors, Jayabheri Enclave Phase - II, Gachibowli(Old Address:12-10-167, MIG- 167,Bharat Nagar Colony, Hyderabad – 500018.)Phone: +91-40-23818475/6Fax : +91-40-23868024Email: info@vccili Aurum, Door No 4-50/P-II/57/4F&5F Plot No 57 4th & 5th Floors Jayabheri Enclave Phase - II, Gachibowli PIN: Tel No: 23818475,23868257,35164910 Fax No: NULL Email: [email protected] Internet: www.vccipl.com
Management
Venkateshwarlu Pulluru, Whole Time Director
Janardhan Das Kabra, Non Executive Independent Director
Lakshman Samala, Non Executive Independent Director
Gattu Gnana Prakash, Non Independent & Non Executive Director
Mayuri Baidya, Non Executive Independent Director
Nishita Kalantri, Company Secretary & Compliance Officer
Sridevi Belide, Non Independent & Non Executive Director
Details
BSE 536565
NSE NULL
ISIN INE314I01036